All In Biotech

Drug Trial Radar · NCT06085521

A Study of LNK01001 Capsule in Patients With Moderate to Severe Atopic Dermatitis

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficiency and Safety of LNK01001 Capsule in Patients With Moderate to Severe Atopic Dermatitis

Last checked: Nov 19, 2026Latest source record: Oct 27, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

150

Actual

Start

Jan 26, 2022

Primary completion

Jun 14, 2023

Study completion Jun 14, 2023

Sponsor

Lead sponsor
Lynk Pharmaceuticals Co., LtdIndustry
Sponsor type
Industry
First posted
Oct 17, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Participants who meet eligibility criteria will be randomized in a 1:1:1 ratio to receive a twice daily oral LNK01001 dose A or LNK01001 dose B or matching placebo for 12 weeks.

Conditions

  • Atopic Dermatitis

Interventions

  • LNK01001 Dose ADrug

    Capsules taken orally

  • LNK01001 Dose BDrug

    Capsules taken orally

  • placeboDrug

    Capsules taken orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change from Baseline in Eczema Area and Severity Index (EASI) ScoreTime frame: week 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Jianzhong Zhang

    Beijing, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.